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OBJECTIVES The long-term (five-year) comparative results of treatment of multivessel coronary artery
disease with stenting or coronary artery bypass grafting (CABG) is at present unknown.
BACKGROUND The Arterial Revascularization Therapies Study (ARTS) was designed to compare CABG
and stenting in patients with multivessel disease.
METHODS A total of 1,205 patients with the potential for equivalent revascularization were randomly
assigned to CABG (n 605) or stent implantation (n 600). The primary clinical end point
was freedom from major adverse cardiac and cerebrovascular events (MACCE) at one year;
MACCE at five-year follow-up constituted the final secondary end point.
RESULTS At five years, there were 48 and 46 deaths in the stent and CABG groups, respectively (8.0%
vs. 7.6%; p  0.83; relative risk [RR], 1.05; 95% confidence interval [CI], 0.71 to 1.55).
Among 208 diabetic patients, mortality was 13.4% in the stent group and 8.3% in the CABG
group (p  0.27; RR, 1.61; 95% CI, 0.71 to 3.63). Overall freedom from death, stroke, or
myocardial infarction was not significantly different between groups (18.2% in the stent group
vs. 14.9% in the surgical group; p  0.14; RR, 1.22; 95% CI, 0.95 to 1.58). The incidence
of repeat revascularization was significantly higher in the stent group (30.3%) than in the
CABG group (8.8%; p  0.001; RR, 3.46;95% CI, 2.61 to 4.60). The composite event-free
survival rate was 58.3% in the stent group and 78.2% in the CABG group (p  0.0001; RR,
1.91;95% CI, 1.60 to 2.28).
CONCLUSIONS At five years there was no difference in mortality between stenting and surgery for multivessel
disease. Furthermore, the incidence of stroke or myocardial infarction was not significantly
different between the two groups. However, overall MACCE was higher in the stent group,
driven by the increased need for repeat revascularization. (J Am Coll Cardiol 2005;46:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.082575–81) © 2005 by the American College of Cardiology Foundation
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emeta-analysis including nine trials of multivessel coronary
rtery disease treated by percutaneous balloon angioplasty
lone or coronary artery bypass grafting (CABG) showed a
tatistically significant benefit in terms of survival in favor of
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004, accepted December 20, 2004.urgery at five and eight years (1). However, these survival
ata were from early studies that did not use stents in the
nitial revascularization procedure. The Stent or Surgery
rial (SoS), which involved the use of stents, reported
imilar findings after a median follow-up of two years (2).
owever, the Argentine Randomized Trial: Coronary An-
ioplasty with Stenting versus Coronary Bypass Surgery
ith Multivessel Disease (ERACI-II) suggested that the
rend in favor of CABG for survival at 2.5 years was no
onger present in the stent era (3).
There are currently no data available on the comparative
urvival after multivessel stenting or CABG beyond three
ears. The present study reports on the five-year survival and
vent-free survival of the patients enrolled in the Arterial
evascularization Therapies Study (ARTS) trial (4).
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he study protocol, summarized here, has been previously
ublished (4,5).
opulation. Between April 1997 and June 1998, 1,205
atients from 67 participating centers were randomized to
ither stent implantation (n  600) or CABG (n  605).
he study population included 208 diabetic patients. The
ndications for revascularization included silent ischemia,
table or unstable angina pectoris, and the presence of at
east two de novo lesions located in different major epicar-
ial coronary arteries, potentially amenable to stent implan-
ation. For each patient, entry into the study required
greement from both surgeon and interventional cardiolo-
ist that an equivalent degree of revascularization could
otentially be obtained using either approach.
Specific exclusion criteria from the randomized trial may
e summarized as follows: left ventricular ejection fraction
30%, left main stenosis, history of a cerebrovascular
ccident, transmural myocardial infarction within the pre-
eding week, and severe hepatic or renal disease and need
or concomitant major surgery. All patients gave written
nformed consent.
ive-year clinical follow-up. The study protocol required
ll patients to have follow-up clinic visits with an electro-
ardiogram at one, two, and three years. In addition, at the
ve-year clinical follow-up, anginal status and use of med-
cations were assessed. Additional information was obtained
y telephone interview or via the referring physician when
eeded. An independent committee adjudicated clinical
vents and electrocardiograms.
ubgroup analysis. Pre-specified analyses were performed
n diabetics versus non-diabetics and two- versus three-
essel disease. In addition, post-hoc analyses were per-
ormed on the following subgroups: proximal left anterior
escending versus non-proximal left anterior descending
esions, renal status, gender, and age.
linical end points and effectiveness. The primary end
oint was defined as the absence of any of the following
ajor adverse cardiac and cerebral events (MACCE) within
2 months after randomization: death (all-cause mortality),
erebrovascular accident, documented non-fatal myocardial
nfarction adjudicated by either new abnormal Q-wave or
redefined enzymatic changes, or repeat revascularization by
oronary stenting or CABG (4,5).
Secondary objectives of the study were to compare both
Abbreviations and Acronyms
ARTS  Arterial Revascularization Therapies Study
CABG  coronary artery bypass grafting
CI  confidence interval
MACCE  major adverse cardiac and cerebral event
PCI  percutaneous coronary intervention
RR  relative risktrategies at three and five years. The MACCE were dounted from the time of randomization, whereas the
linical status and medications were assessed at predeter-
ined times of one, two, three, and five years post-procedure.
f 1,205 patients enrolled in the trial, complete follow-up was
vailable at five years in 590 of 600 (98.3%) stent patients and
84 of 605 (96.6%) CABG patients (Fig. 1).
tatistical analysis. Statistical analysis was performed with
AS 6.12 software (SAS Institute Inc., Chicago, Illinois).
inary outcome variables are reported as frequencies and
ercentages and were compared in terms of relative risk with
5% confidence intervals calculated by the formula of
reenland and Robins (6). The Fisher exact test was used
or categorical variables. All analyses were based on the
ntention-to-treat principle, and statistical tests were two-
ailed. Event-free survival was estimated using the Kaplan-
eier method, and differences were assessed using the
og-rank test. The sample size calculation to achieve ade-
uate power for an inferiority study was based on the
ifference in event-free survival at one year (4). For this
ve-year report on late outcomes, no new calculations were
erformed.
ESULTS
able 1 shows the baseline and procedural characteristics of
he ARTS trial’s randomized patients. The randomized
roups were similar with respect to their demographic and
natomic characteristics. Five patients, one assigned to
tenting and four assigned to surgery, did not undergo
oronary revascularization and instead continued to receive
nly medical therapy (4). The average interval between
andomization and treatment was 27  39 days (range, 0 to
62 days) for patients in the surgery group and 11 16 days
range, 0 to 173 days) for patients in the stenting group.
hree patients died while waiting for surgery, 6 patients
andomly assigned to stent implantation were instead
reated surgically, and 19 patients randomly assigned to
ypass surgery were instead treated with stent implantation.
total of 99% of patients in the stenting group (593
atients) and 93% in the surgery group (579 patients)
eceived the assigned treatment. An equivalent anatomical
egree of revascularization was achieved in each group.
During the initial hospital stay, after complicated or
nsatisfactory angioplasty procedures, 14 patients assigned
o stent implantation underwent bypass surgery, 3 urgently
nd 11 electively. Conversely, two patients underwent an
ngioplasty procedure after surgical revascularization during
heir initial hospital stay (Fig. 1).
ive-year clinical outcome. At five years, there were 48
eaths in the stent group and 46 deaths in the surgical
roup, which represents 8.0% and 7.6% of the respective
ohorts (p  0.83; relative risk [RR], 1.05; 95% confidence
nterval [CI], 0.71 to 1.55) (Table 2, Fig. 2). The incidence
f cardiac death was not significantly different between the
roups (Table 3). Of the 94 deaths, 6 occurred within 30
ays after a repeat revascularization procedure.
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August 16, 2005:575–81 Five-Year Outcomes in the ARTS TrialThe incidence of death, stroke, or myocardial infarction
as not significantly different among the groups (18.2% in
he stent group vs. 14.9% in the surgical group; p  0.14;
R, 1.22; 95% CI, 0.95 to 1.58).
The incidence of repeat revascularization was signifi-
antly higher in the stent group (30.3%) than in the CABG
roup (8.8%; p  0.001; RR, 3.46; 95% CI, 2.61 to 4.60).
t the end of five years, 10.5% of patients originally
ssigned to stenting required CABG and 23.2% underwent
second percutaneous coronary intervention (PCI). Con-
ersely, 1.2% of patients assigned to CABG required re-
peration and 8.3% required revascularization with PCI. In
he stent group, the majority of re-interventions (69%) took
lace within the first year, whereas in the CABG group, the
ajority of the re-interventions (57%) occurred after the
rst year. The overall MACCE-free survival at five years
as 58.3% in the stent group and 78.2% in the CABG
roup (p  0.0001).
At five years, there was a significant difference in the
resence of anginal symptoms between the two treatment
roups (21.2% of the stent patients vs. 15.5% of the CABG
atients, p  0.05). More of the stent patients were on
hort-acting nitrates (6.1% vs. 2.4%, p  0.003), long-
cting nitrates (19.6% vs. 11.6%, p  0.001), beta-blocker
herapy (53.9% vs. 46.5%, p  0.016), and calcium-channel
Figure 1. Flow chart. CABGntagonists (29.1% vs. 18.9%, p  0.001).
able 1. Baseline and Procedural Characteristics of
RTS Population
Stent
(n  600)
CABG
(n  605)
o. of patients not revascularized 1 7*
o. of cross-overs 6 19
ge (yrs),  SD 61  10 61  9
ale gender (%) 77 76
ody mass index (kg/m2),  SD† 27.2  3.7 27.4  3.7
iabetes (%)‡ 19 16
ypertension (%)§ 45 45
ypercholesterolemia (%) 58 58
urrent smoker (%) 28 26
revious myocardial infarction 44 42
nstable angina (%) 37 35
jection fraction (%) 61  12 60  13
o. of diseased vessels (% of patients)
1 2 0
2 68 67
3 30 33
o. of lesions with stenosis 50% 2.83  1.02 2.80  1.04
o. of lesions treated 2.60  1.10 2.60  1.00
esions treated with stent (%) 89 –
atients with arterial conduit (%) – 93
Includes three patients who died while waiting for surgery. †The body mass index is
etermined as the weight in kilograms divided by the square of the height in meters.
Diabetes was defined as a patient whose condition was controlled by diet, oral
ypoglycemics, or insulin. §Hypertension was defined as a blood pressure of 160/95
m Hg in repeated measurements or patients on anti-hypertensive medication and/or
equiring medical treatment. Hypercholesterolemia was defined as a total cholesterol
6.5 mmol/l or patients on anti-hypercholesterolemic therapy.
CABG  coronary artery bypass graft; SD  standard deviation.
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Five-Year Outcomes in the ARTS Trial August 16, 2005:575–81atients with diabetes. In patients with diabetes, those
ho underwent stenting had a mortality rate of 13.4%,
ersus 8.3% in those who underwent CABG (p 0.27; RR,
.61; 95% CI, 0.71 to 3.63) (Tables 4 and 5). Within the
tent group, diabetic patients had a significantly higher
ortality rate than non-diabetic patients (13.4% vs. 6.8%; p
0.03; RR, 1.98; 95% CI, 1.11 to 3.52). In stent diabetic
atients, death was attributed to a cardiac cause in 50% of
ases versus 38% (p 0.43; RR, 1.32; 95% CI, 0.68 to 2.58)
n non-diabetic stent patients. There was no significant
ortality difference between the diabetic and non-diabetic
atients within the CABG group (8.3% vs. 7.5%; p  0.8;
R, 1.12; 95% CI, 0.54 to 2.32).
Diabetic patients treated with stenting also had a lower
vent-free survival at five years than non-diabetic pa-
ients. The MACCE rate at five years in diabetic patients
Table 2. Total Number of Patients With Majo
(Randomization to 1, 3, and 5 Years)
Stent
Event n* %*
Death
0–1 yr 15 2.5
0–3 yrs 22 3.7
0–5 yrs 48 8.0
CVA
0–1 yr 12 2.0
0–3 yrs 20 3.3
0–5 yrs 23 3.8
Q-wave MI
0–1 yr 32 5.3
0–3 yrs 36 6.0
0–5 yrs 40 6.7
Non–Q-wave MI
0–1 yr 4 0.7
0–3 yrs 8 1.3
0–5 yrs 11 1.8
Composite death/CVA/MI
0–1 yr 57 9.5
0–3 yrs 79 13.2
0–5 yrs 109 18.2
CABG
0–1 yr 40 6.7
0–3 yrs 55 9.2
0–5 yrs 63 10.5
Repeat PCI
0–1 yr 94 15.7
0–3 yrs 120 20.0
0–5 yrs 139 23.2
Any revascularization
0–1 yr 126 21.0
0–3 yrs 160 26.7
0–5 yrs 182 30.3
Any event
0–1 yr 159 26.5
0–3 yrs 205 34.2
0–5 yrs 250 41.7
*Number of patients and percentage of patients with at least o
indicated in the table. †p value calculated by the Fisher Exa
CABG  coronary artery bypass grafting; CI  confide
infarction; PCI  percutaneous coronary intervention.reated with stents was 54.5%, versus 38.7% in non- diabetics (p  0.003). Conversely, there was no signifi-
ant difference in the five-year MACCE rate between
iabetic and non-diabetic patients treated with CABG
25.0% vs. 21.2%, p  0.42). The difference in MACCE
ate between diabetic and non-diabetic patients treated
ith stenting is largely attributable to the higher rate of
epeat revascularization in diabetic patients (42.9% vs.
7.5%, p  0.002).
wo- versus three-vessel treatment. There was no signif-
cant difference in event-free survival rate between patients
ith two or three vessels treated with stenting (56.7% vs.
0.1%) or CABG (79.4% vs. 75.7%), respectively. However,
he event-free survival rate was significantly higher for
atients treated with CABG than with stenting for both two
nd three vessels (p  0.001 and p  0.001, respectively).
ther subgroup analyses. There were also no significant
inical Events Within Interval of Time
CABG
Relative Risk
(95% CI) p Value†* %*
7 2.8 0.89 (0.45–1.77) 0.86
8 4.6 0.79 (0.46–1.37) 0.47
6 7.6 1.05 (0.71–1.55) 0.83
3 2.1 0.93 (0.43–2.02) 1.00
0 3.3 1.01 (0.55–1.86) 1.00
1 3.5 1.10 (0.62–1.97) 0.76
6 4.3 1.24 (0.75–2.06) 0.42
0 5.0 1.21 (0.76–1.94) 0.45
4 5.6 1.19 (0.76–1.85) 0.47
2 0.3 2.02 (0.37–10.97) 0.45
4 0.7 2.02 (0.61–6.67) 0.26
5 0.8 2.22 (0.78–6.35) 0.14
2 8.6 1.11 (0.77–1.58) 0.62
0 11.6 1.14 (0.84–1.54) 0.43
0 14.9 1.22 (0.95–1.58) 0.14
4 0.7 10.0 (3.63–28.0)  0.001
7 1.2 7.92 (3.64–17.3)  0.001
7 1.2 9.08 (4.19–19.7)  0.001
0 3.3 4.74 (2.96–7.58)  0.001
7 6.1 3.27 (2.30–4.65)  0.001
0 8.3 2.80 (2.07–3.80)  0.001
3 3.8 5.52 (3.59–8.49)  0.001
0 6.6 4.03 (2.91–5.60)  0.001
3 8.8 3.46 (2.61–4.60)  0.001
3 12.1 2.20 (1.71–2.83)  0.001
3 17.0 2.01 (1.63–2.47)  0.001
2 21.8 1.91 (1.60–2.28)  0.001
urrence of the specified clinical event during the time interval
.
terval; CVA  cerebrovascular accident; MI  myocardialr Cl
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August 16, 2005:575–81 Five-Year Outcomes in the ARTS Trialent groups based on renal function, gender, age, or
ypercholesterolemia at the time of randomization. At five
ears, 65.9% in the stent group and 61.5% in the CABG
roup were on lipid-lowering agents. Outcomes in patients
ho were treated for proximal left anterior descending
esions or otherwise were not significantly different stratified
y treatment group.
ISCUSSION
his is the first randomized trial to report on five-year
utcomes of patients with multivessel coronary artery dis-
ase treated with bare metal stenting versus CABG. Al-
hough this study was not specifically powered to detect a
ifference in five-year mortality, there was no clinically
elevant difference (p  0.83) with these two forms of
reatment. This contemporary finding differs from the
eta-analysis of previous randomized trials of balloon
ngioplasty alone versus CABG conducted in patients with
ultivessel disease, which showed a significantly higher
ortality rate with percutaneous treatment at five years (risk
ifference, 2.3%; 95% CI, 0.29 to 4.3%; p  0.025) (1).
In this study, mortality in the CABG arm was 7.6% at
igure 2. (A) Kaplan-Meier curves showing freedom from death. (B)
yocardial infarction or revascularization. (C) Kaplan-Meier curves sho
evascularization. (D) Kaplan-Meier curves showing freedom from revascuve years, lower than the composite death rate of 8.9% seen
on the CABG patients from the meta-analysis (1), evidence
hat improved peri-operative management and intra-
perative techniques over time have resulted in a reduction
n mortality. Similarly, mortality in the stent arm was 8.0%,
risk difference of 0.4% (95% CI, 1.1% to 1.9%; p  0.83).
rom one to five years, the risk difference changes from
.3% in favor of stenting at one year, to 0.9% in favor of
able 3. Listing of Deaths and Causes of Death
Randomized to
PCI
n  600
CABG
n  605
otal deaths 48 46
nknown 2 1
on-cardiac 25 28
ardiac 21 17
Related to repeat revascularization* 5 1
Repeat revascularization within 30
days of index procedure
4† 0
Repeat revascularization 30 days
of index procedure
1 1
Cardiac death related to repeat revascularization was defined as death within 30 days
f repeat procedure. †Three died within 30 days of the index procedure as a result of
ubacute stent thrombosis, one died of a myocardial tear after CABG for a failed PCI
n-Meier curves showing freedom from death/cerebrovascular accident/
freedom from death/cerebrovascular accident/myocardial infarction or
tion. CABG  coronary artery bypass grafting.Kaplan day 12.
Abbreviations as in Table 2.
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Five-Year Outcomes in the ARTS Trial August 16, 2005:575–81tenting at three years, to 0.4% in favor of CABG at five
ears (all not significant), indicating a strong effect of
hance. Furthermore, this difference is not clinically relevant
nd is much lower than the 2.3% of the meta-analysis.
There was a 3.3% absolute difference in the composite
nd point of death, stroke, and myocardial infarction in
avor of CABG, primarily driven by a higher incidence of
yocardial infarctions in the stent arm. Although sugges-
ive, this study was underpowered to detect a significant
ifference in the end point. Based on this difference, a
opulation of 4,000 patients would be required for statistical
ignificance.
The risk difference for revascularization at five years, as
eported in this same meta-analysis, was 38% (95% CI, 30%
o 47%). Specifically, the risk difference for subsequent
ABG was 24% and for subsequent percutaneous translu-
inal coronary angioplasty was 23%. The current observed
ifferences in the ARTS trial for any revascularization at five
ears is 21.5%, for subsequent CABG is 9.3%, and for
ubsequent PCI is 14.9%. It is worth noting that almost
0% of patients initially treated with stenting did not
equire CABG over the succeeding five years. The differ-
Table 4. Major Adverse Cardiac Events at 5 Y
According to Treatment
Stent Diabetes
n  112
n* (%*)
Death 15 (13.4)
CVA 7 (6.3)
MI 12 (10.7)
Q-wave MI 9 (8.0)
Non–Q-wave MI 3 (2.7)
Composite death/CVA/MI 28 (25.0)
(re) CABG 17 (15.2)
(re) PTCA 34 (30.4)
Any revascularization 48 (42.9)
Any MACCE 61 (54.5)
*Number of patients and percentage of patients with at least o
indicated in the table. †p value calculated using the Fisher e
Abbreviations as in Table 2.
Table 5. Major Adverse Cardiac Events at 5 Y
According to Treatment
Stent
Non-Diabetic
n  488
n* (%*)
Death 33 (6.8)
CVA 16 (3.3)
MI 38 (7.8)
Q-wave MI 31 (6.4)
Non–Q-wave MI 8 (1.6)
Composite death/CVA/MI 81 (16.6)
(re) CABG 46 (9.4)
(re) PTCA 105 (21.5)
Any revascularization 134 (27.5)
Any MACCE 189 (38.7)
*Number of patients and percentage of patients with at least o
indicated in the table. †p value calculated using the Fisher exact te
Abbreviations as in Table 2.nce in the rate of repeat revascularization between the two
roups increases over time from 17.2% at 1 year to 21.5% at
ve years without a concomitant difference in mortality over
his time period. Despite the additional risk of repeat
evascularization in the stent group compared with the
ABG group, this did not translate into an increase in
ortality (Table 3).
In this study, four-fifths of all patients in both groups were
ree of anginal complaints at five years. Although significantly
ifferent, this high proportion of patients free of symptoms is
ncouraging in this population of patients with chronic mul-
ivessel coronary artery disease. Correspondingly, more stent
atients than CABG patients were on anti-anginal medica-
ions (p  0.001) at five-year follow-up.
In diabetic patients from three trials comparing balloon
ngioplasty with surgery, the risk difference for all death was
.6% in favor of CABG (p  0.01; 95% CI, 2.2% to 15%)
n  537 patients) at four years (1). In the present study
nvolving 208 diabetic patients, mortality at five years was
.1% higher in stent patients compared with CABG pa-
ients (p  0.27). Conversely, in non-diabetic patients the
ortality rate was 0.7% lower in the stent cohort. However,
in Patients With Diabetes Stratified
ass Diabetes
n  96
n* (%*)
Relative Risk
(95% CI)
Stent Versus
CABG
p Value†
8 (8.3) 1.61 (0.71–3.63) 0.27
7 (7.3) 0.86 (0.31–2.36) 0.79
7 (7.3) 1.47 (0.60–3.59) 0.47
4 (4.2) 1.93 (0.61–6.07) 0.39
3 (3.1) 0.86 (0.18–4.15) 1.00
19 (19.8) 1.26 (0.76–2.11) 0.41
2 (2.1) 7.29 (1.73–30.7) 0.001
9 (9.4) 3.24 (1.64–6.41) 0.001
10 (10.4) 4.11 (2.20–7.68) 0.001
24 (25.0) 2.18 (1.48–3.20) 0.001
urrence of the specified clinical event during the time interval
st.
in Patients Without Diabetes Stratified
ypass
-Diabetic
 509
* (%*)
Relative Risk
(95% CI)
Stent Versus
CABG
p Value†
8 (7.5) 0.91 (0.58–1.42) 0.71
4 (2.8) 1.19 (0.59–2.42) 0.71
1 (6.1) 1.28 (0.81–2.02) 0.32
0 (5.9) 1.08 (0.66–1.75) 0.79
2 (0.4) 4.17 (0.89–19.55) 0.059
1 (13.9) 1.19 (0.89–1.60) 0.25
5 (1.0) 9.60 (3.85–23.95) 0.001
1 (8.1) 2.67 (1.90–3.75) 0.001
3 (8.4) 3.25 (2.36–4.48) 0.001
8 (21.2) 1.83 (1.49–2.23) 0.001
urrence of the specified clinical event during the time intervalears
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August 16, 2005:575–81 Five-Year Outcomes in the ARTS Trialhe study was not powered to show mortality differences
etween diabetic and non-diabetic patients.
Repeat revascularization was higher in diabetic patients
andomized to the stent arm versus CABG (an absolute
ifference of 32.5% [42.9% vs. 10.9%, respectively]), com-
ared with non-diabetic patients (a 19.1% absolute differ-
nce [27.5% vs. 8.4%, respectively, both p  0.001]). Based
n the available evidence, surgery should continue to be
iewed as the preferred therapy for diabetic patients with
ultivessel disease when using bare metal stents.
The advent of drug-eluting stents has drastically reduced
he need for repeat revascularization in both diabetic and
on-diabetic patients. The relative reduction in need for
e-intervention with drug-eluting stents is very similar in
iabetic and non-diabetic patients (7,8). The difference in
utcomes seen between bare metal stents versus CABG for
he treatment of multivessel disease is likely to narrow
ubstantially with the advent of drug-eluting stents. The
.S. National Institutes of Health is sponsoring a large
ulticenter trial specifically to evaluate the difference in
utcomes in diabetic patients with multivessel coronary
isease treated with drug-eluting stents versus CABG. A
uropean multicenter trial comparing drug-eluting stents
ersus CABG for the treatment of multivessel and left main
tem coronary disease in an all-comers population is cur-
ently in progress.
Despite the increasing age and concomitant increased
o-morbidity of patients presenting for CABG, clinical
utcomes have continued to improve (9). This was evident
rom the lower mortality seen in the CABG arm of this
tudy compared with the older studies. The off-pump
oronary bypass technique, developed to minimize the
nvasiveness of CABG, has in several large retrospective
tudies suggested a reduction in morbidity and/or mortality
hen compared with CABG (10). Larger randomized trials
re required to address this issue definitively because the
hree reported randomized prospective studies comparing
ff-pump coronary bypass with CABG were not large
nough to detect a difference in operative mortality or stroke
10). Finally, the routine use of post-procedural medica-
ions—aspirin, statins, and control of risk factors—willurther improve outcomes in both the CABG and the stent
roups in future trials.
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